MaxCyte is a commercial cell engineering company engaged on providing enabling platform technologies to improve cell-based research and development as well as cell therapeutic discovery, development and commercialization. Co.'s ExPERT platform, which is based on its Flow Electroporation technology, has been designed to address this cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes: three instruments, which Co. calls the ATx, STx and GTx. The MXCT average annual return since 2021 is shown above.
The Average Annual Return on the MXCT average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether MXCT average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the MXCT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|